You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither SPIE nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the SPIE website.
4 March 2016Clinical development of BLZ-100 for real-time optical imaging of tumors during resection
Complete initial resection can give cancer patients the best opportunity for long-term survival. There is unmet need in
surgical oncology for optical imaging that enables simple and precise visualization of tumors and consistent contrast with
surrounding normal tissues. Near-infrared (NIR) contrast agents and camera systems that can detect them represent an
area of active research and development. The investigational Tumor Paint agent BLZ-100 is a conjugate of a chlorotoxin
peptide and the NIR dye indocyanine green (ICG) that has been shown to specifically bind to a broad range of solid
tumors. Clinical efficacy studies with BLZ-100 are in progress, a necessary step in bringing the product into clinical
practice. To ensure a product that will be useful for and accepted by surgeons, the early clinical development of BLZ-
100 incorporates multiple tumor types and imaging devices so that surgeon feedback covers the range of anticipated
clinical uses. Key contrast agent characteristics include safety, specificity, flexibility in timing between dose and surgery,
and breadth of tumor types recognized. Imaging devices should use wavelengths that are optimal for the contrast agent,
be sensitive enough that contrast agent dosing can be adjusted for optimal contrast, include real-time video display of
fluorescence and white light image, and be simple for surgeons to use with minimal disruption of surgical flow. Rapid
entry into clinical studies provides the best opportunity for early surgeon feedback, enabling development of agents and
devices that will gain broad acceptance and provide information that helps surgeons achieve more complete and precise
resections.
The alert did not successfully save. Please try again later.
Heather L. Franklin, Dennis M. Miller, Teresa Hedges, Jeff Perry, Julia Parrish-Novak, "Clinical development of BLZ-100 for real-time optical imaging of tumors during resection," Proc. SPIE 9696, Molecular-Guided Surgery: Molecules, Devices, and Applications II, 96960V (4 March 2016); https://doi.org/10.1117/12.2224856